Vico Therapeutics B.V. announced that it has received ?54 million ($60 million) in a round of funding co-led by new investor, Ackermans & Van Haaren NV and from returning investors, DROIA nv, EQT Life Sciences and Kurma Partners SA on January 5, 2024. The transaction included participation from returning investors, Polaris Venture Partners, Inc., Pureos Partners AG and Eurazeo Investment Manager. As a part of transaction, Jeroen Vangindertael at Ackermans & Van Haaren NV, will join the company's board of directors.